Shattuck Labs (STTK) to Release Earnings on Thursday

Shattuck Labs (NASDAQ:STTK) will likely be issuing its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of ($0.12) per share and revenue of $0.1670 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 5, 2026 at 6:30 AM ET.

Shattuck Labs (NASDAQ:STTK) last announced its earnings results on Thursday, March 5th. The company reported ($0.12) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.12). The business had revenue of ($1.00) million for the quarter, compared to analyst estimates of $0.17 million. On average, analysts expect Shattuck Labs to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Shattuck Labs Trading Up 1.5%

Shares of STTK opened at $6.04 on Thursday. Shattuck Labs has a 12 month low of $0.69 and a 12 month high of $6.26. The firm’s 50 day moving average is $4.52 and its 200-day moving average is $3.12. The stock has a market capitalization of $432.22 million, a PE ratio of -7.84 and a beta of 1.55.

Hedge Funds Weigh In On Shattuck Labs

Institutional investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC bought a new position in Shattuck Labs in the 3rd quarter valued at approximately $38,000. AQR Capital Management LLC grew its stake in shares of Shattuck Labs by 265.4% during the first quarter. AQR Capital Management LLC now owns 43,169 shares of the company’s stock worth $41,000 after buying an additional 31,355 shares during the last quarter. Qube Research & Technologies Ltd acquired a new position in shares of Shattuck Labs during the second quarter worth $44,000. Squarepoint Ops LLC acquired a new position in shares of Shattuck Labs during the third quarter worth $46,000. Finally, Bridgeway Capital Management LLC lifted its stake in shares of Shattuck Labs by 147.5% in the 2nd quarter. Bridgeway Capital Management LLC now owns 92,300 shares of the company’s stock valued at $73,000 after acquiring an additional 55,000 shares during the last quarter. 58.74% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on STTK. HC Wainwright raised Shattuck Labs from a “neutral” rating to a “buy” rating and set a $6.00 price objective for the company in a report on Monday, December 1st. Needham & Company LLC assumed coverage on Shattuck Labs in a report on Friday, March 6th. They set a “buy” rating and a $25.00 target price on the stock. Wedbush raised their price target on Shattuck Labs from $4.00 to $8.00 and gave the stock an “outperform” rating in a research report on Friday, March 6th. TD Cowen reaffirmed a “buy” rating on shares of Shattuck Labs in a research note on Friday, March 6th. Finally, Citigroup increased their price objective on shares of Shattuck Labs from $4.00 to $7.00 and gave the stock a “neutral” rating in a research note on Friday, March 13th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Shattuck Labs currently has a consensus rating of “Moderate Buy” and an average price target of $10.50.

About Shattuck Labs

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.